eResearchTechnology and Pharma Bio-Research Sign Agreement to Deliver Integrated Cardiac Safety and Clinical Pharmacology Servic
15 May 2004 - 12:05AM
PR Newswire (US)
eResearchTechnology and Pharma Bio-Research Sign Agreement to
Deliver Integrated Cardiac Safety and Clinical Pharmacology
Services Sixth Clinical Research Organization Enters into Digital
Cardiac Safety Monitoring Services Agreement with
eResearchTechnology PHILADELPHIA, May 14 /PRNewswire-FirstCall/ --
eResearchTechnology, Inc. (eRT), , a leading provider of
centralized electrocardiographic (ECG) collection and
interpretation services, today announced it has entered into an
agreement with Pharma Bio-Research Group B.V. (PBR), a leading
provider of Phase I/IIA clinical trials and support services to the
pharmaceutical and biotechnology industries. This alliance, the
sixth for eRT and second in Europe, enables testing of new drug
candidates in conjunction with emerging international cardiac
safety regulatory guidance and technical standards. Under the
agreement, Pharma Bio-Research will conduct clinical trials at its
Phase I unit in Zuidlaren, The Netherlands, while eRT will perform
digital collection, measurement, interpretation, review and
distribution of cardiac safety data through its EXPeRT
workflow-enabled data handling technology. The eRT technology is
the first solution designed explicitly to meet emerging
international guidance and standards related to cardiac safety
monitoring services. "Pharma Bio-Research has extensive clinical
research experience since 1984, including the conduct of more
complex Phase I studies," said Robert Brown, senior vice president
of outsourcing partnerships for eRT. "Our alliance presents a great
opportunity for eRT to expand its Thorough Phase I ECG Study
partnership program within Europe and will help to meet increasing
demand from international drug development organizations for the
ability to conduct Thorough Phase I ECG studies in Europe. We are
pleased to be announcing the Pharma Bio-Research agreement and look
forward to working closely with the Pharma Bio-Research team to
ensure effective execution of Thorough Phase I ECG studies." "eRT
is the world leading provider of digital ECG collection, processing
and interpretation," said Willem Jan Drijfhout, Ph.D., Chief
Scientific Officer of PBR. "As the European leader of complex phase
I/IIA trials, the partnership between PBR and eRT represents for us
another opportunity to serve our clients even better in their need
for Thorough Phase I ECG studies, especially since regulations are
now demanding such studies to be conducted on a large scale. We
look forward to intensifying our relationship with eRT under the
current agreement and are convinced that the professional staff of
eRT fits well with the high quality culture of PBR." Based in
Philadelphia, Pa., eResearchTechnology, Inc. (http://www.ert.com/)
is a provider of technology and services to the pharmaceutical,
biotechnology and medical device industries on a global basis. The
company is a market leader in providing centralized core-diagnostic
electrocardiographic (ECG) technology and services to evaluate
cardiac safety in clinical development. The company is also a
leader in providing technology and services to streamline the
clinical trials process by enabling its customers to automate the
collection, analysis and distribution of clinical data in all
phases of clinical development. Based in Zuidlaren, The
Netherlands, Pharma Bio-Research Group B.V. is a full service CRO
with 140 total beds and offers the full range of services for phase
I/IIA clinical research, bioanalysis, biometrics and report writing
with the most competitive time lines, excellent quality,
reliability and efficiency. Since 1984, PBR has carried out more
than 1,000 clinical studies and more than 2,000 bioanalytical
studies. Statements included in this release may constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements involve a
number of risks and uncertainties such as competitive factors,
technological development, market demand and the company's ability
to obtain new contracts and accurately estimate net revenues due to
variability in size, scope and duration of projects, and internal
issues in the sponsoring client. As a result, actual results may
differ materially from any financial outlooks stated herein.
Further information on potential factors that could affect the
company's financial results can be found in the company's reports
on Form 10-K and 10-Q filed with the Securities and Exchange
Commission. DATASOURCE: eResearchTechnology, Inc. CONTACT: Joan
Sterlacci, eResearchTechnology, +1-908-203-6473; or Matt Hayden,
Hayden Communications, +1-858-456-4533, for eResearchTechnology Web
site: http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jun 2024 to Jul 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about East Resources Acquisition Company (NASDAQ): 0 recent articles
More Eresearch Tech (MM) News Articles